How many insider trades does FilingIQ track for CCCC?

FilingIQ tracks 318 Form 4 insider transactions for CCCC (C4 Therapeutics, Inc.), covering filings from Oct 6, 2020 onwards. 4 of those were filed in the last 90 days.

Are CCCC insiders net buyers or net sellers?

Across the full Form 4 history for CCCC, 5 transactions (2%) were open-market purchases and 54 (17%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does CCCC insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is CCCC in?

C4 Therapeutics, Inc. (CCCC) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $185.11M.

CCCC insider trading

NasdaqGS Healthcare

C4 Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

318

Last 90 days

Buys / sells

2% / 17%

Market cap

$185.11M

About C4 Therapeutics, Inc.

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 clinical trials targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting BRAF V600 mutant that is in Phase 1/2 clinical trials to treat melanoma, colorectal cancer, and other solid malignancies; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor with an L858R mutation in non-small cell lung cancer. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; Merck KGaA; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Company website: www.c4therapeutics.com

CCCC insider activity at a glance

FilingIQ has scored 318 insider transactions for CCCC since Oct 6, 2020. The most recent filing in our index is dated Apr 1, 2026.

Across the full history, 5 open-market purchases and 54 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on CCCC insider trades is 55.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live CCCC trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for CCCC?: FilingIQ tracks 318 Form 4 insider transactions for CCCC (C4 Therapeutics, Inc.), covering filings from Oct 6, 2020 onwards. 4 of those were filed in the last 90 days.
Are CCCC insiders net buyers or net sellers?: Across the full Form 4 history for CCCC, 5 transactions (2%) were open-market purchases and 54 (17%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does CCCC insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is CCCC in?: C4 Therapeutics, Inc. (CCCC) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $185.11M.

Methodology & sources

Every CCCC insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.